• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Anchor Therapeutics

edit

Anchor Therapeutics, Inc., a discovery and pre-clinical development-stage biopharmaceutical company, develops pharmaceutical candidates to address cancer, inflammation, metabolism, heart disease, and pain. The company develops Pepducin lipopeptide drug candidates, which are molecules that target the intracellular domains of G protein coupled receptors (GPCRs) to allosterically modulate GPCR signaling. Its Pepducin technology platform is used to develop lipopeptide allosteric modulators for intractable GPCR targets. The company was formerly known as Ascent Therapeutics, Inc. and changed its name to Anchor Therapeutics, Inc. in March 2010. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.

Recent Milestones

edit

• 
  Anchor Therapeutics added Micahel J.Berendt as Board Of Directors. (1/1/12)
  Posted 5/23/13 at 1:25pm
• 
  Anchor Therapeutics — Anchor Therapeutics, Ortho-McNeil Strike $480M Deal (9/10/10)
  Posted 9/13/10 at 1:09am via dowjones.com
• 
  Anchor Therapeutics — Anchor Therapeutics licensing deal to net up to $480M (9/9/10)
  Posted 9/9/10 at 7:05am via masshightech.com
• 
  Anchor Therapeutics received $10M in Series B funding. (8/20/10)
  Posted 8/20/10 at 5:49pm via anchortx.com
• 
  Anchor Therapeutics added Stephen Hunt as Chief Scientific Officer.
  Posted 5/23/13 at 1:25pm
• 
  Anchor Therapeutics added Thomas McMurry as Acting President, and Senior Vice President, Preclinical R&D.
  Posted 5/23/13 at 1:25pm
• 
  Anchor Therapeutics added Frederick Jones as President and CEO.
  Posted 8/20/10 at 5:49pm
• 
  Anchor Therapeutics added Jochen Knolle as Board of Directors.
  Posted 5/23/13 at 1:25pm
• 
  Anchor Therapeutics added Cynthia Lavoie as Board Of Directors.
  Posted 5/23/13 at 1:25pm
• 
  Anchor Therapeutics added Thomas Sakmar as Board of Directors.
  Posted 5/23/13 at 1:25pm

Videos

Screenshots

edit

Sources

1. Anchor Therapeutics Secures $10 Million Series B Financing to Advance Pepducin Drug Candidates (anchortx.com) [edit]
Anchor Therapeutics licensing deal to net up to $480M (masshightech.com) [edit]
Anchor Therapeutics, Ortho-McNeil Strike $480M Deal (fis.dowjones.com) [edit]